USD $8.80-8.80 / Gram
USD $6.00-9.00 / Gram
USD $8.80-8.80 / Gram
USD $6.00-9.00 / Gram
USD $2.00-10.00 / Kilogram
USD $11,000.00-12,000.00 / Metric Ton
USD $10.00-100.00 / Kilogram
USD $2.00-10.00 / Kilogram
USD $11,000.00-12,000.00 / Metric Ton
afatinib is a new generation of oral small molecule tyrosine kinase inhibitor (tki) and is the first irreversible erbb family blocker that acts on the entire erbb family, including egfr. unlike the first-generation reversible egfr tki, afatinib binds irreversibly to egfr, thereby shutting down the cancer cell signaling pathway and inhibiting tumor growth.
product name | afatinib (bibw 2992) | cas number | 39081-18-2 |
moculer formula | c24h25n5o3fcl | moculer weigh | 485.944 |
appearance and traits | white powder | density | 1.380g/cm3 |
melting point | 100 - 102 °c | boiling point | 676.917 at 760 mmhg |
flash point | 363.186°c | refractive index | 1.668 |
afatinib (bibw2992) irreversibly inhibits egfr/her2 including egfr(wt), egfr(l858r), egfr(l858r/t790m) and her2 with ic50 of 0.5 nm, 0.4 nm, 10 nm and 14 nm in cell-free assays, respectively. afatinib (bibw 2992) is the second-generation potent and irreversible dual inhibitor of the epidermal growth factor receptor (egfr) and human epidermal growth factor receptor 2 (her2) tyrosine kinase.
1 local advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) gene-sensitive mutations, previously untreated with egfr tyrosine kinase inhibitor (tki)
2 local advanced or metastatic squamous type of non-small cell lung cancer (nsclc) with or without disease progression during platinum chemotherapy.
packing and shipping